Beta-lactam antibiotics represent the oldest yet the most commonly used class of antibiotic for treating bacterial infections in the clinic. However, the use of broad-spectrum antibiotics is a also known risk factor for various diseases such as colon cancer as well as fungi infections. As the beta-lactam antibiotics inhibit the biosynthesis of the bacterial peptiodglycan, we focus on the changes in the peptidoglycan profile of the gut microbiota niche upon exposure to beta-lactam drugs. Using various assays, we have established that the role of the peptidoglycan fragments as underlying mechsanisms contributing to the diseases.

Beta-lactam antibiotic exposure alters the gut microbiota peptidoglycan profile

ACS Fall 2021

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.